OptimizeRx preliminary Q4 revenue ~$20.3M record; guides 2022 revenue $80-85M

OptimizeRx Corp

2021-FY EPS reported $0.02 revenue$61,292,598

Preliminary Q4 2021 revenue ~$20.3M (record); full-year revenue rose 42% YoY.
GAAP net income $0.6M; record quarterly adjusted EBITDA $4.0M.
2022 guidance: revenue $80-85M (31-39% growth); gross margins 57-60%.
New KPIs: avg revenue per top-20 pharma manufacturer $2.5M; net revenue retention 127%; revenue per FTE $730K.
Top 20 pharma customer penetration increased to 95% from 85% YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.